Toleranzia AB is a pioneering brand that harnesses the power of the immune system to develop treatments for autoimmune orphan diseases. Their groundbreaking medicines target the underlying causes of these conditions, offering the potential to cure or significantly alleviate the disease, rather than merely reducing symptoms like current treatments. Toleranzia's primary focus is on myasthenia gravis (MG), an autoimmune nerve and muscle disease, for which they are developing their drug candidate TOL2.

They are also working on ANCA vasculitis, an autoimmune blood vessel disease, with their drug candidate TOL3. Both these conditions are rare diseases, presenting a significant medical need and a substantial market potential. With their innovative technology portfolio, Toleranzia is at the forefront of transforming the way autoimmunity is treated